MERCK

By June 19, 2019 Closed

A  Six  Month  Phase II/III,  Randomized, Double- Blind, PlaceboControlled   Clinical  Trial to Evaluate  the Safety,Tolerability,  and Efficacy of Telcagepant   (MK-0974)  for Prevention  of Menstrually Related Migraine  in Female Patients with Episodic Migraine

Leave a Reply